JP2019510001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510001A5 JP2019510001A5 JP2018544185A JP2018544185A JP2019510001A5 JP 2019510001 A5 JP2019510001 A5 JP 2019510001A5 JP 2018544185 A JP2018544185 A JP 2018544185A JP 2018544185 A JP2018544185 A JP 2018544185A JP 2019510001 A5 JP2019510001 A5 JP 2019510001A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- use according
- item
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022023843A JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298366P | 2016-02-22 | 2016-02-22 | |
| US62/298,366 | 2016-02-22 | ||
| PCT/US2017/018938 WO2017147182A1 (en) | 2016-02-22 | 2017-02-22 | Actrii antagonists for use in increasing immune activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023843A Division JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510001A JP2019510001A (ja) | 2019-04-11 |
| JP2019510001A5 true JP2019510001A5 (https=) | 2020-04-09 |
| JP7058606B2 JP7058606B2 (ja) | 2022-04-22 |
Family
ID=59629767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544185A Expired - Fee Related JP7058606B2 (ja) | 2016-02-22 | 2017-02-22 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
| JP2022023843A Pending JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022023843A Pending JP2022062277A (ja) | 2016-02-22 | 2022-02-18 | 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20170240639A1 (https=) |
| EP (1) | EP3420002A4 (https=) |
| JP (2) | JP7058606B2 (https=) |
| KR (1) | KR20180128405A (https=) |
| CN (1) | CN109311998A (https=) |
| AU (1) | AU2017222526A1 (https=) |
| CA (1) | CA3014197A1 (https=) |
| WO (1) | WO2017147182A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| PT3286206T (pt) | 2015-04-22 | 2021-04-01 | Biogen Ma Inc | Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular |
| BR112019006993A2 (pt) | 2016-10-05 | 2019-09-03 | Acceleron Pharma Inc | heteromultímeros de alk4:actriib e usos dos mesmos |
| CN110430890B (zh) | 2016-11-10 | 2024-09-10 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| JP7246617B2 (ja) * | 2017-02-01 | 2023-03-28 | アクセルロン ファーマ インコーポレイテッド | 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN108129572B (zh) * | 2018-01-04 | 2021-01-29 | 河南大学 | 人GDF11-Fc融合蛋白在治疗溃疡性结肠炎中的应用 |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| JP7405772B2 (ja) | 2018-05-09 | 2023-12-26 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物 |
| EP3807308A4 (en) * | 2018-06-15 | 2022-03-16 | Acceleron Pharma Inc. | BI AND TRIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| AU2020284038A1 (en) * | 2019-05-30 | 2021-12-02 | Acceleron Pharma Inc. | ActRII-binding proteins and uses thereof |
| JP7663559B2 (ja) | 2019-09-03 | 2025-04-16 | ノバルティス アーゲー | Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療 |
| AU2020364139A1 (en) * | 2019-10-10 | 2022-05-26 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modified stem cells and methods of use thereof |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| IL296394A (en) | 2020-03-20 | 2022-11-01 | Keros Therapeutics Inc | Type ii activin receptor chimeras and methods of using them |
| JP2024532345A (ja) * | 2021-09-03 | 2024-09-05 | ラエクナ セラピューティクス シャンハイ カンパニー リミテッド | 抗ａｃｖｒ２ａ抗体及びその使用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2111229B1 (en) * | 2007-02-01 | 2013-04-10 | Acceleron Pharma, Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss |
| KR20180085825A (ko) * | 2009-08-13 | 2018-07-27 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| BR112012005225B8 (pt) * | 2009-09-09 | 2023-01-10 | Acceleron Pharma Inc | Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| KR101438265B1 (ko) * | 2011-04-04 | 2014-09-05 | 한국생명공학연구원 | Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
| WO2013063536A1 (en) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| GR1007832B (el) * | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| JP2015525230A (ja) * | 2012-06-11 | 2015-09-03 | アムジエン・インコーポレーテツド | デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用 |
| WO2014172448A2 (en) * | 2013-04-17 | 2014-10-23 | Anaptysbio, Inc. | Antibodies directed against activin receptor type ii (actrii) |
| KR20170035891A (ko) * | 2014-06-13 | 2017-03-31 | 산타 마리아 바이오테라퓨틱스, 인코포레이티드 | 제형화된 수용체 폴리펩타이드 및 관련 방법 |
| WO2016090035A2 (en) * | 2014-12-02 | 2016-06-09 | La Jolla Institute For Allergy And Immunology | Modulators of activin and methods for modulating immune responses and t follicular helper cells |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
-
2017
- 2017-02-22 AU AU2017222526A patent/AU2017222526A1/en not_active Abandoned
- 2017-02-22 WO PCT/US2017/018938 patent/WO2017147182A1/en not_active Ceased
- 2017-02-22 US US15/439,386 patent/US20170240639A1/en not_active Abandoned
- 2017-02-22 JP JP2018544185A patent/JP7058606B2/ja not_active Expired - Fee Related
- 2017-02-22 EP EP17757142.9A patent/EP3420002A4/en active Pending
- 2017-02-22 CA CA3014197A patent/CA3014197A1/en active Pending
- 2017-02-22 KR KR1020187027012A patent/KR20180128405A/ko not_active Abandoned
- 2017-02-22 CN CN201780024969.4A patent/CN109311998A/zh active Pending
-
2022
- 2022-02-18 JP JP2022023843A patent/JP2022062277A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510001A5 (https=) | ||
| Jiang et al. | cGAS-STING, an important pathway in cancer immunotherapy | |
| Elster et al. | HER2-family signalling mechanisms, clinical implications and targeting in breast cancer | |
| Jones et al. | Evolving novel anti-HER2 strategies | |
| Duffy et al. | Immunological off-target effects of standard treatments in gastrointestinal cancers | |
| Arora et al. | Immunotherapy in colorectal cancer: for the select few or all? | |
| Duarte et al. | Gastric cancer: basic aspects | |
| Dasanu et al. | Immune alterations and emerging immunotherapeutic approaches in lung cancer | |
| Marelli et al. | A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer | |
| Luedke et al. | Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation | |
| Goldberg et al. | Enhancing cancer immunotherapy via activation of innate immunity | |
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| Zibelman et al. | Overview of current treatment options and investigational targeted therapies for locally advanced squamous cell carcinoma of the head and neck | |
| Kersh et al. | Targeted therapies: immunologic effects and potential applications outside of cancer | |
| JP2021534094A (ja) | 未分化リンパ腫キナーゼ阻害剤と組み合わせてｅｇｆ／ｅｇｆｒ経路を抑制するための方法および組成物 | |
| Rekers et al. | Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives | |
| Lam et al. | Refractory metastatic colorectal cancer: current challenges and future prospects | |
| AU2020241963A1 (en) | Treatment of cancers using sEphB4-HSA fusion proteins | |
| JP7148399B2 (ja) | 悪性疾患に対する併用療法 | |
| JP2018509423A5 (https=) | ||
| Bai et al. | Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer | |
| Hwang et al. | Emerging egfr-targeted therapy in head and neck cancer: A review | |
| Terrero et al. | Role of immunotherapy in advanced gastroesophageal cancer | |
| CN105407916A (zh) | 二价疫苗组合物以及其用于治疗肿瘤的用途 | |
| Kim et al. | Current status and perspective of immunotherapy in gastrointestinal cancers |